Copper and zinc in stage I multiple myeloma: relation with ceruloplasmin, lipid peroxidation, and superoxide dismutase activity

References

[1] Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25–35.10.1007/978-3-540-85772-3_2Search in Google Scholar PubMed

[2] Harousseau JL. New insights into the biology and advances in the management of multiple myeloma. Best Pract Res Clin Haematol. 2007;20:569–70.10.1016/j.beha.2007.10.003Search in Google Scholar PubMed

[3] Rajabli N, Naeimi-Tabeie M, Jahangirrad A, Sedaghat SM, Semnani S, Roshandel G. Epidemiology of leukemia and multiple myeloma in Golestan, Iran. Asian Pac J Cancer Prev. 2013;14:2333–6.10.7314/APJCP.2013.14.4.2333Search in Google Scholar PubMed

[4] Berenson JR. Etiology of multiple myeloma: what’s new. Semin Oncol. 1999;26:2–9.Search in Google Scholar PubMed

[5] Milkovic L, Siems W, Siems R, Zarkovic N. Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. Curr Pharm Des. 2014;20:6529–42.10.2174/1381612820666140826152822Search in Google Scholar PubMed

[6] Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5:9–19.10.1097/WOX.0b013e3182439613Search in Google Scholar PubMed

[7] Akbarzadeh M, Movassaghpour AA, Ghanbari H, Kheirandish M, Maroufi NF, Rahbarghazi R, et al. The potential therapeutic effect of melatonin on human ovarian cancer by inhibition of invasion and migration of cancer stem cells. Sci Rep. 2017;7:17062.10.1038/s41598-017-16940-ySearch in Google Scholar PubMed

[8] Tas F, Hansel H, Belce A, Ilvan S, Argon A, Camlica H, et al. Oxidative stress in breast cancer. Med Oncol. 2005;22:11–5.10.1385/MO:22:1:011Search in Google Scholar PubMed

[9] Carillon J, Rouanet JM, Cristol JP, Brion R. Superoxide dismutase administration, a potential therapy against oxidative stress related diseases: several routes of supplementation and proposal of an original mechanism of action. Pharm Res. 2013;30:2718–28.10.1007/s11095-013-1113-5Search in Google Scholar PubMed

[10] Fotiou K, Vaiopoulos G, Lilakos K, Giannopoulos A, Mandalenaki K, Marinos G, et al. Serum ceruloplasmin as a marker in prostate cancer. Minerva Urol Nefrol. 2007;59:407–11.Search in Google Scholar PubMed

[11] Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME. Zinc and human health: an update. Arch Toxicol. 2011;86:521–34.10.1007/s00204-011-0775-1Search in Google Scholar PubMed

[12] Zowczak M, Iskra M, Torlinski L, Cofta S. Analysis of serum copper and zinc concentrations in cancer patients. Biol Trace Elem Res. 2001;82:1–8.10.1385/BTER:82:1-3:001Search in Google Scholar PubMed

[13] Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15:316–28.10.1016/j.numecd.2005.05.003Search in Google Scholar PubMed

[14] Faridvand Y, Oskuyi AE, Khadem-Ansari MH. Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma. Redox Rep. 2015;21(5):204–8.10.1179/1351000215Y.0000000034Search in Google Scholar PubMed PubMed Central

[15] Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996;313:17–29.10.1042/bj3130017Search in Google Scholar PubMed PubMed Central

[16] Roque AT, Gambeloni RZ, Felitti S, Ribeiro ML, Santos JC. Inflammation-induced oxidative stress in breast cancer patients. Med Oncol. 2015;32:263.10.1007/s12032-015-0709-5Search in Google Scholar PubMed

[17] Poli G, Leonarduzzi G, Biasi F, Chiarpotto E. Oxidative stress and cell signalling. Curr Med Chem. 2004;11:1163–82.10.2174/0929867043365323Search in Google Scholar PubMed

[18] Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014:360438.10.1155/2014/360438Search in Google Scholar PubMed PubMed Central

[19] Kasapovic J, Pejic S, Todorovic A, Stojiljkovic V, Pajovic SB. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages. Cell Biochem Funct. 2008;26:723–30.10.1002/cbf.1499Search in Google Scholar PubMed

[20] Otsuka M, Oshinbe A, LeGeros RZ, Tokudome Y, Ito A, Otsuka K, et al. Efficacy of the injectable calcium phosphate ceramics suspensions containing magnesium, zinc and fluoride on the bone mineral deficiency in ovariectomized rats. J Pharm Sci. 2008;97:421–32.10.1002/jps.21131Search in Google Scholar PubMed

[21] Sharif R, Thomas P, Zalewski P, Fenech M. The role of zinc in genomic stability. Mutat Res. 2011;733:111–21.10.1016/j.mrfmmm.2011.08.009Search in Google Scholar PubMed

[22] Lodh M, Goswami B, Gupta N, Patra SK, Saxena A. Assessment of oxidative stress and inflammatory process in patients of multiple myeloma. Indian J Clin Biochem. 2013;27:410–3.10.1007/s12291-012-0222-ySearch in Google Scholar PubMed PubMed Central

[23] Zima T, Spicka I, Stipek S, Crkovska J, Platenik J, Merta M, et al. [Lipid peroxidation and activity of antioxidative enzymes in patients with multiple myeloma]. Cas Lek Cesk. 1996;135:14–7.Search in Google Scholar PubMed

[24] Mehdi WA, Zainulabdeen JA, Mehde AA. Investigation of the antioxidant status in multiple myeloma patients: effects of therapy. Asian Pac J Cancer Prev. 2013;14:3663–7.10.7314/APJCP.2013.14.6.3663Search in Google Scholar PubMed

[25] Sharma A, Tripathi M, Satyam A, Kumar L. Study of antioxidant levels in patients with multiple myeloma. Leuk Lymphoma. 2009;50:809–15.10.1080/10428190902802323Search in Google Scholar PubMed

[26] Singh BP, Dwivedi S, Dhakad U, Murthy RC, Choubey VK, Goel A, et al. Serum levels of trace elements in patients with prostate cancer. Asian Pac J Cancer Prev. 2014;15:2625–9.10.7314/APJCP.2014.15.6.2625Search in Google Scholar PubMed

[27] Buentzel J, Bruns F, Glatzel M, Garayev A, Muecke R, Kisters K, et al. Zinc concentrations in serum during head and neck cancer progression. Anticancer Res. 2007;27:1941–3.Search in Google Scholar PubMed

[28] Boz A, Evliyaoglu O, Yildirim M, Erkan N, Karaca B. The value of serum zinc, copper, ceruloplasmin levels in patients with gastrointestinal tract cancers. Turk J Gastroenterol. 2005;16:81–4.Search in Google Scholar PubMed

[29] Golabek T, Darewicz B, Borawska M, Socha K, Markiewicz R, Kudelski J. Copper, zinc, and Cu/Zn ratio in transitional cell carcinoma of the bladder. Urol Int. 2012;89:342–7.10.1159/000341976Search in Google Scholar PubMed

[30] Wachowicz B, Krajewski T, Zbikowska H. Protective effect of ceruloplasmin against lipid peroxidation in blood platelets. Acta Biochim Pol. 1990;37:261–6.Search in Google Scholar PubMed

[31] Knekt P, Aromaa A, Maatela J, Rissanen A, Hakama M, Aaran RK, et al. Serum ceruloplasmin and the risk of cancer in Finland. Br J Cancer. 1992;65:292–6.10.1038/bjc.1992.58Search in Google Scholar PubMed PubMed Central

[32] Gadjeva V, Kutchukova D, Aladjov E, Georgieva R. Correlation between plasma malondialdehyde and ceruloplasmin activity in patients with malignant haematological diseases. Trakia J Sci. 2005;3:29–33.Search in Google Scholar

[33] Ellidag HY, Aydin O, Eren E, Yilmaz N, Ergin M. Decreased HDL-dependent paraoxonase and arylesterase enzyme activity may indicate a worse prognosis in multiple myeloma. Asian Pac J Cancer Prev. 2014;15:9847–51.10.7314/APJCP.2014.15.22.9847Search in Google Scholar PubMed

[34] Gangemi S, Allegra A, Alonci A, Cristani M, Russo S, Speciale A, et al. Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflamm Res. 2012;61:1063–7.10.1007/s00011-012-0498-7Search in Google Scholar PubMed

[35] Toyokuni S. Molecular mechanisms of oxidative stress-induced carcinogenesis: from epidemiology to oxygenomics. IUBMB Life. 2008;60:441–7.10.1002/iub.61Search in Google Scholar PubMed